{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T01:40:10Z","timestamp":1759974010166,"version":"build-2065373602"},"reference-count":65,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2007,2,1]],"date-time":"2007-02-01T00:00:00Z","timestamp":1170288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,2,1]],"date-time":"2007-02-01T00:00:00Z","timestamp":1170288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["M\u00e9decine et Maladies Infectieuses"],"published-print":{"date-parts":[[2007,2]]},"DOI":"10.1016\/j.medmal.2006.11.002","type":"journal-article","created":{"date-parts":[[2007,2,3]],"date-time":"2007-02-03T02:46:33Z","timestamp":1170470793000},"page":"71-76","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Actualit\u00e9s sur\u00a0le\u00a0posaconazole"],"prefix":"10.1016","volume":"37","author":[{"given":"A.","family":"Paugam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.medmal.2006.11.002_bib1","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1128\/AAC.48.2.568-574.2004","article-title":"Three-dimensional models of wild-type and mutated forms of cytochrome P450 14-alpha-sterol demethylases from Aspergillus fumigatus and Candida albicans provide insights into posaconazole binding","volume":"48","author":"Xiao","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"issue":"10","key":"10.1016\/j.medmal.2006.11.002_bib2","doi-asserted-by":"crossref","first-page":"3690","DOI":"10.1128\/AAC.48.10.3690-3696.2004","article-title":"Posaconazole is a potent inhibitor of sterol 14-alpha-demethylation in yeasts and molds","volume":"48","author":"Munayyer","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.medmal.2006.11.002_bib3","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1046\/j.1365-2125.2003.01977.x","article-title":"Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults","volume":"57","author":"Courtney","year":"2004","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.medmal.2006.11.002_bib4","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2165\/00003088-200544020-00006","article-title":"Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations","volume":"44","author":"Ezzet","year":"2005","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.medmal.2006.11.002_bib5","unstructured":"Lewis J, et al. 15th ISHAM; 2003; abstract 256."},{"issue":"3","key":"10.1016\/j.medmal.2006.11.002_bib6","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1128\/AAC.48.3.804-808.2004","article-title":"Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men","volume":"48","author":"Courtney","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"issue":"9","key":"10.1016\/j.medmal.2006.11.002_bib7","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1128\/AAC.47.9.2788-2795.2003","article-title":"Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults","volume":"47","author":"Courtney","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"issue":"11","key":"10.1016\/j.medmal.2006.11.002_bib8","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.2165\/00003495-200565110-00007","article-title":"Posaconazole","volume":"65","author":"Keating","year":"2005","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.medmal.2006.11.002_bib9","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1586\/14787210.3.4.467","article-title":"Posaconazole: clinical pharmacology and potential for management of fungal infections","volume":"3","author":"Groll","year":"2005","journal-title":"Expert Rev. Anti Infect. Ther."},{"issue":"2","key":"10.1016\/j.medmal.2006.11.002_bib10","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/0091270004271402","article-title":"Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease","volume":"45","author":"Courtney","year":"2005","journal-title":"J. Clin. Pharmacol."},{"issue":"6","key":"10.1016\/j.medmal.2006.11.002_bib11","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1517\/13543784.15.6.579","article-title":"Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations","volume":"15","author":"Aperis","year":"2006","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"12","key":"10.1016\/j.medmal.2006.11.002_bib12","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S1473-3099(05)70297-8","article-title":"Posaconazole: a broad-spectrum triazole antifungal","volume":"5","author":"Torres","year":"2005","journal-title":"Lancet Infect. Dis."},{"issue":"5","key":"10.1016\/j.medmal.2006.11.002_bib13","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.ejps.2004.01.005","article-title":"Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study","volume":"21","author":"Wexler","year":"2004","journal-title":"Eur. J. Pharm. Sci."},{"issue":"12","key":"10.1016\/j.medmal.2006.11.002_bib14","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1086\/504328","article-title":"Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections","volume":"42","author":"Raad","year":"2006","journal-title":"Clin. Infect. Dis."},{"issue":"2","key":"10.1016\/j.medmal.2006.11.002_bib15","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1128\/AAC.50.2.658-666.2006","article-title":"Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection","volume":"50","author":"Ullmann","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"10.1016\/j.medmal.2006.11.002_bib16","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1128\/AAC.00163-06","article-title":"In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts","volume":"50","author":"Sabatelli","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.medmal.2006.11.002_bib17","unstructured":"National Committee for Laboratory Standards 2002. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved Standard M38-A. National Committee for Laboratory Standards, Waye, Pa."},{"key":"10.1016\/j.medmal.2006.11.002_bib18","unstructured":"National Committee for Laboratory Standards 2002. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved Standard M27-A2(22). National Committee for Laboratory Standards, Waye, Pa."},{"issue":"6","key":"10.1016\/j.medmal.2006.11.002_bib19","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1128\/AAC.00162-06","article-title":"In vitro activities of 10 combinations of antifungal agents against the multiresistant pathogen Scopulariopsis brevicaulis","volume":"50","author":"Cuenca-Estrella","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.medmal.2006.11.002_bib20","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/jac\/44.2.283","article-title":"In vitro comparative activity of UR-9825, itraconazole and fluconazole against clinical isolates of Candida spp","volume":"44","author":"Ramos","year":"1999","journal-title":"J. Antimicrob. Chemother."},{"issue":"8","key":"10.1016\/j.medmal.2006.11.002_bib21","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1128\/AAC.48.8.3107-3111.2004","article-title":"In vitro activities of ravuconazole and four other antifungal agents against fluconazole-resistant or -susceptible clinical yeast isolates","volume":"48","author":"Cuenca-Estrella","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"10.1016\/j.medmal.2006.11.002_bib22","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1128\/AAC.46.6.1723-1727.2002","article-title":"In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6970 clinical isolates of Candida spp","volume":"46","author":"Pfaller","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"issue":"7","key":"10.1016\/j.medmal.2006.11.002_bib23","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1128\/JCM.42.7.3142-3146.2004","article-title":"Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the Artemis Antifungal Surveillance Program conducted in 2001 and 2002","volume":"42","author":"Pfaller","year":"2004","journal-title":"J. Clin. Microbiol."},{"issue":"4","key":"10.1016\/j.medmal.2006.11.002_bib24","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1128\/AAC.46.4.1032-1037.2002","volume":"46","author":"Pfaller","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"issue":"8","key":"10.1016\/j.medmal.2006.11.002_bib25","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1128\/AAC.40.8.1910","article-title":"In vitro and in vivo efficacies of the azole SCH-56592 against Cryptococcus neoformans","volume":"40","author":"Perfect","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"issue":"5","key":"10.1016\/j.medmal.2006.11.002_bib26","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1128\/JCM.43.5.2163-2167.2005","article-title":"Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004)","volume":"43","author":"Pfaller","year":"2005","journal-title":"J. Clin. Microbiol."},{"issue":"3","key":"10.1016\/j.medmal.2006.11.002_bib27","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1128\/AAC.50.3.917-921.2006","article-title":"Head-to-head comparison of the activities of currently available antifungal agents against 3378 Spanish clinical isolates of yeasts and filamentous fungi","volume":"50","author":"Cuenca-Estrella","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.medmal.2006.11.002_bib28","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1093\/jac\/46.2.229","article-title":"A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH-56592)","volume":"46","author":"Manavathu","year":"2000","journal-title":"J. Antimicrob. Chemother."},{"issue":"10","key":"10.1016\/j.medmal.2006.11.002_bib29","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1128\/JCM.40.10.3776-3781.2002","article-title":"Optimal testing conditions for determining MICs and minimum fungicidal concentrations of new and established antifungal agents for uncommon molds: NCCLS collaborative study","volume":"40","author":"Espinel-Ingroff","year":"2002","journal-title":"J. Clin. Microbiol."},{"issue":"10","key":"10.1016\/j.medmal.2006.11.002_bib30","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1111\/j.1469-0691.2006.01481.x","article-title":"Clinical manifestations, treatment and outcome of Paecilomyces lilacinus infections","volume":"12","author":"Pastor","year":"2006","journal-title":"Clin. Microbiol. Infect."},{"issue":"8","key":"10.1016\/j.medmal.2006.11.002_bib31","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1128\/AAC.44.8.2017-2022.2000","article-title":"In vitro and in vivo activities of SCH-56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida","volume":"44","author":"Cacciapuoti","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"issue":"10","key":"10.1016\/j.medmal.2006.11.002_bib32","doi-asserted-by":"crossref","first-page":"3715","DOI":"10.1128\/AAC.48.10.3715-3719.2004","article-title":"Antifungal therapy of murine Aspergillus terreus infection","volume":"48","author":"Graybill","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.medmal.2006.11.002_bib33","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1128\/AAC.44.3.780-782.2000","article-title":"Efficacy of SCH-56592 in a rabbit model of invasive aspergillosis","volume":"44","author":"Kirkpatrick","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"10.1016\/j.medmal.2006.11.002_bib34","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/jac\/42.4.539","article-title":"SCH 56592 treatment of murine invasive aspergillosis","volume":"42","author":"Graybill","year":"1998","journal-title":"J. Antimicrob. Chemother."},{"issue":"2","key":"10.1016\/j.medmal.2006.11.002_bib35","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1086\/377210","article-title":"Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B","volume":"188","author":"Walsh","year":"2003","journal-title":"J. Infect. Dis."},{"issue":"10","key":"10.1016\/j.medmal.2006.11.002_bib36","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1128\/AAC.48.10.4063-4066.2004","article-title":"Efficacy of posaconazole in a murine model of central nervous system aspergillosis","volume":"48","author":"Imai","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"10.1016\/j.medmal.2006.11.002_bib37","doi-asserted-by":"crossref","first-page":"302","DOI":"10.5326\/0420302","article-title":"Use of posaconazole in the management of invasive orbital aspergillosis in a cat","volume":"42","author":"McLellan","year":"2006","journal-title":"J. Am. Anim. Hosp. Assoc."},{"issue":"1","key":"10.1016\/j.medmal.2006.11.002_bib38","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1128\/AAC.48.1.137-142.2004","article-title":"Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis","volume":"48","author":"Andes","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"issue":"5","key":"10.1016\/j.medmal.2006.11.002_bib39","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1128\/AAC.44.5.1159-1162.2000","article-title":"SCH-56592, amphotericin B, or itraconazole therapy of experimental murine cerebral phaeohyphomycosis due to Ramichloridium obovoideum (\u201cRamichloridium mackenziei\u201d)","volume":"44","author":"Al-Abdely","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"10.1016\/j.medmal.2006.11.002_bib40","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/jac\/48.6.769","article-title":"Activity of the new antifungal triazole, posaconazole, against Cryptococcus neoformans","volume":"48","author":"Barchiesi","year":"2001","journal-title":"J. Antimicrob. Chemother."},{"issue":"3","key":"10.1016\/j.medmal.2006.11.002_bib41","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1128\/AAC.43.3.589","article-title":"Treatment of murine fusariosis with SCH-56592","volume":"43","author":"Lozano-Chiu","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.medmal.2006.11.002_bib42","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1128\/AAC.43.2.322","article-title":"Comparison of a new triazole antifungal agent, SCH-56592, with itraconazole and amphotericin B for treatment of histoplasmosis in immunocompetent mice","volume":"43","author":"Connolly","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"issue":"10","key":"10.1016\/j.medmal.2006.11.002_bib43","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1128\/AAC.44.10.2604-2608.2000","article-title":"Comparison of a new triazole, posaconazole, with itraconazole and amphotericin B for treatment of histoplasmosis following pulmonary challenge in immunocompromised mice","volume":"44","author":"Connolly","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.medmal.2006.11.002_bib44","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/jac\/dkg020","article-title":"In vitro susceptibilities of zygomycetes to conventional and new antifungals","volume":"51","author":"Dannaoui","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"issue":"5","key":"10.1016\/j.medmal.2006.11.002_bib45","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1128\/AAC.46.5.1352-1356.2002","article-title":"In vitro and in vivo activities of posaconazole against Coccidioides immitis","volume":"46","author":"Gonzalez","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"issue":"7","key":"10.1016\/j.medmal.2006.11.002_bib46","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1128\/AAC.41.7.1558","article-title":"Activity of the triazole SCH-56592 against disseminated murine coccidioidomycosis","volume":"41","author":"Lutz","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"10.1016\/j.medmal.2006.11.002_bib47","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1128\/AAC.47.4.1436-1438.2003","article-title":"Activity of posaconazole against Pseudallescheria boydii: in vitro and in vivo assays","volume":"47","author":"Gonzalez","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"10.1016\/j.medmal.2006.11.002_bib48","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1590\/S0036-46652005000600006","article-title":"Posaconazole treatment of refractory eumycetoma and chromoblastomycosis","volume":"47","author":"Negroni","year":"2005","journal-title":"Rev. Inst. Med. Trop. Sao Paulo"},{"issue":"1","key":"10.1016\/j.medmal.2006.11.002_bib49","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/00000441-200607000-00009","article-title":"First case of Penicillium marneffei fungemia in Greece and strain susceptibility to five licensed systemic antifungal agents and posaconazole","volume":"332","author":"Filiotou","year":"2006","journal-title":"Am. J. Med. Sci."},{"key":"10.1016\/j.medmal.2006.11.002_bib50","article-title":"Salvage treatment of histoplasmosis with posaconazole","author":"Restrepo","year":"2006","journal-title":"J. Infect."},{"issue":"6","key":"10.1016\/j.medmal.2006.11.002_bib51","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1093\/jac\/dkl133","article-title":"Activity of newer triazoles against Histoplasma capsulatum from patients with AIDS who failed fluconazole","volume":"57","author":"Wheat","year":"2006","journal-title":"J. Antimicrob. Chemother."},{"issue":"7","key":"10.1016\/j.medmal.2006.11.002_bib52","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1002\/cncr.20554","article-title":"Aspergillus terreus: an emerging amphotericin B-resistant opportunistic mold in patients with hematologic malignancies","volume":"101","author":"Hachem","year":"2004","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.medmal.2006.11.002_bib53","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1086\/508774","article-title":"Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial","volume":"44","author":"Walsh","year":"2007","journal-title":"Clin. Inf. Dis."},{"issue":"1","key":"10.1016\/j.medmal.2006.11.002_bib54","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1128\/AAC.50.1.126-133.2006","article-title":"Posaconazole as salvage therapy for zygomycosis","volume":"50","author":"Greenberg","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"issue":"7","key":"10.1016\/j.medmal.2006.11.002_bib55","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1086\/500212","article-title":"Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases","volume":"42","author":"van Burik","year":"2006","journal-title":"Clin. Infect. Dis."},{"issue":"11","key":"10.1016\/j.medmal.2006.11.002_bib56","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1086\/375075","article-title":"Mucormycosis (zygomycosis) in a heart-kidney transplant recipient: recovery after posaconazole therapy","volume":"36","author":"Tobon","year":"2003","journal-title":"Clin. Infect. Dis."},{"issue":"5","key":"10.1016\/j.medmal.2006.11.002_bib57","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1097\/01.PCC.0000235255.68759.05","article-title":"Successful use of posaconazole in a pediatric case of fungal necrotizing fasciitis","volume":"7","author":"De Decker","year":"2006","journal-title":"Pediatr. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.medmal.2006.11.002_bib58","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ajo.2006.02.053","article-title":"Periorbital zygomycosis (mucormycosis) treated with posaconazole","volume":"142","author":"Rutar","year":"2006","journal-title":"Am. J. Ophthalmol."},{"issue":"10","key":"10.1016\/j.medmal.2006.11.002_bib59","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1086\/503425","article-title":"Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions","volume":"42","author":"Raad","year":"2006","journal-title":"Clin. Infect. Dis."},{"issue":"7","key":"10.1016\/j.medmal.2006.11.002_bib60","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1136\/bjo.86.7.829-a","article-title":"Ocular and systemic posaconazole (SCH-56592) treatment of invasive Fusarium solani keratitis and endophthalmitis","volume":"86","author":"Sponsel","year":"2002","journal-title":"Br. J. Ophthalmol."},{"issue":"4","key":"10.1016\/j.medmal.2006.11.002_bib61","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1093\/jac\/dki288","article-title":"Activity of posaconazole in the treatment of central nervous system fungal infections","volume":"56","author":"Pitisuttithum","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"issue":"6","key":"10.1016\/j.medmal.2006.11.002_bib62","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.ijantimicag.2005.12.012","article-title":"Cytoskeleton reassembly in cardiomyocytes infected by Trypanosoma cruzi is triggered by treatment with ergosterol biosynthesis inhibitors","volume":"27","author":"Silva","year":"2006","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"3","key":"10.1016\/j.medmal.2006.11.002_bib63","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1021\/jm050691f","article-title":"Amiodarone has intrinsic anti-Trypanosoma cruzi activity and acts synergistically with posaconazole","volume":"49","author":"Benaim","year":"2006","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.medmal.2006.11.002_bib64","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1128\/AAC.44.1.150-155.2000","article-title":"Activities of the triazole derivative SCH-56592 (posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hosts","volume":"44","author":"Molina","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"issue":"12","key":"10.1016\/j.medmal.2006.11.002_bib65","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1128\/AAC.43.12.2910","article-title":"Efficacy of the triazole SCH 56592 against Leishmania amazonensis and Leishmania donovani in experimental murine cutaneous and visceral leishmaniases","volume":"43","author":"Al-Abdely","year":"1999","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["M\u00e9decine et Maladies Infectieuses"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0399077X06003507?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0399077X06003507?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T01:01:43Z","timestamp":1759971703000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0399077X06003507"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2]]},"references-count":65,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,2]]}},"alternative-id":["S0399077X06003507"],"URL":"https:\/\/doi.org\/10.1016\/j.medmal.2006.11.002","relation":{},"ISSN":["0399-077X"],"issn-type":[{"type":"print","value":"0399-077X"}],"subject":[],"published":{"date-parts":[[2007,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Actualit\u00e9s sur\u00a0le\u00a0posaconazole","name":"articletitle","label":"Article Title"},{"value":"M\u00e9decine et Maladies Infectieuses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medmal.2006.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}